

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### The effect of allopurinol on serum uric acid level and arterial blood pressure in hemodialysis patients

#### Protocol summary

##### Summary

This study is a single blind, controlled clinical trial to determine the effect of Allopurinol on serum uric acid level and arterial blood pressure in hemodialysis patients with hypertension and hyperuricemia. The main inclusion criteria are mild, moderate or severe hypertension and hyperuricemia (greater than 7 and 6 in men and women respectively) and excluding criteria are irregular use of the drug and the development of severe side effects. The study population consists of 146 patients undergoing hemodialysis. The patients are randomly divided into 2 groups. The first group will receive allopurinol as uric acid-lowering agent 100 mg daily for three months and the second group receive placebo as control for the same time. Then at the end of first, second and third months measurement of blood pressure and uric acid is done as the primary outcomes.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2014120820243N1**

Registration date: **2015-01-03, 1393/10/13**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2015-01-03, 1393/10/13

##### Registrant information

###### Name

Seyed mohammad kazem Sadeghi

###### Name of organization / entity

Health Ministry

###### Country

Iran (Islamic Republic of)

##### Phone

+98 83 3421 3325

##### Email address

smk.sadeghi@kums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Kermanshah University of Medical Sciences

##### Expected recruitment start date

2014-12-22, 1393/10/01

##### Expected recruitment end date

2015-01-21, 1393/11/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of allopurinol on serum uric acid level and arterial blood pressure in hemodialysis patients

##### Public title

Allopurinol prescription for better control of blood pressure

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Hypertension; hyperuricemia; patients must be on dialysis since at least 3 months ago; no taking diuretics; no taking other uric acid lowering agents; have signed the informed consent. Exclusion criteria: irregular use of the drug; presence of severe adverse effects

##### Age

From **18 years** old

##### Gender

Both

##### Phase

N/A

### Groups that have been masked

No information

### Sample size

Target sample size: **146**

### Randomization (investigator's opinion)

N/A

### Randomization description

### Blinding (investigator's opinion)

Single blinded

### Blinding description

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Kermanshah university of medical sciences

##### Street address

Shahid Beheshti Blv

##### City

Kermanshah

##### Postal code

#### Approval date

2014-03-04, 1392/12/13

#### Ethics committee reference number

53868

## Health conditions studied

### 1

#### Description of health condition studied

hypertension

#### ICD-10 code

112.0

#### ICD-10 code description

Hypertensive renal disease with renal failur

### 2

#### Description of health condition studied

hyperuricemia

#### ICD-10 code

E79.0

#### ICD-10 code description

Asymptomatic hyperuricaemia

## Primary outcomes

### 1

#### Description

Blood pressure

#### Timepoint

before intervention,one and two and three months after begining

#### Method of measurement

by mercury barometer in scale of mm Hg

### 2

#### Description

uric acid

#### Timepoint

Before intervention 1,2 and 3 months later

#### Method of measurement

by blood sampling

## Secondary outcomes

### 1

#### Description

the drug side effects

#### Timepoint

Before intervention 1,2 and 3 months later

#### Method of measurement

clinical manifestations and CBC

## Intervention groups

### 1

#### Description

Intervention group:they get Allopurinol 100 mg one tablet daily for three months with meal(lunch ordinner)

#### Category

Treatment - Drugs

### 2

#### Description

control:multivitamine one tablet daily for three months

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Imamreza Hospital

##### Full name of responsible person

Seyed Mohammadkazem sadeghi internal medicine resident

##### Street address

Imamreza Hospital Dialysis ward

##### City

Kermanshah

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Hamzehee Koroush

**Street address**

Shahid Beheshti Street

**City**

Kermanshah

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kermanshah University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Kermanshah University Of Medical Sciences

**Full name of responsible person**

Seyed Mohammad kazem Sadeghi

**Position**

Internal resident

**Other areas of specialty/work**

**Street address**

Kermanshah Imam reza Hospital Internal office

**City**

Kermanshah

**Postal code**

**Phone**

+98 83 3427 6309

**Fax**

**Email**

smk.sadeghi@kums.ac.ir smksadeghi9@gmail.com

**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Kermanshah University Medical Sciences

**Full name of responsible person**

Hamidreza Omrani

**Position**

Nephrologist

**Other areas of specialty/work**

**Street address**

Imam reza hospital

**City**

Kermanshah

**Postal code**

**Phone**

+98 834276309

**Fax**

**Email**

hamidomrani@gmail.com

**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Seyed Mohammad kazem Sadeghi

**Position**

Internal resident

**Other areas of specialty/work**

**Street address**

Imam Reza Hospital

**City**

Kermanshah

**Postal code**

**Phone**

+98 83 3427 6309

**Fax**

**Email**

smk.sadeghi@kums.ac.ir

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*